Molecular mechanisms of glioma invasiveness: The role of proteases

Nature Reviews Cancer

Volumn 3, Issue 7, 2003, Pages 489-501

  Rao, Jasti S ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; AG 3360; BATIMASTAT; CATHEPSIN B; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE A; GELATINASE B; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; MESSENGER RNA; PROTEINASE; PROTEINASE INHIBITOR; SYNAPTOPHYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 4; UNCLASSIFIED DRUG; UROKINASE; UROKINASE RECEPTOR; CELL SURFACE RECEPTOR; MATRIX METALLOPROTEINASE; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR, UROKINASE RECEPTORS;

BRAIN TISSUE; BRAIN TUMOR; CANCER INVASION; CELL INFILTRATION; CELL INVASION; ENZYME ANALYSIS; ENZYME MECHANISM; GLIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; INHIBITION KINETICS; MOLECULAR MECHANICS; MORTALITY; PRIORITY JOURNAL; REVIEW; TUMOR RECURRENCE; CENTRAL NERVOUS SYSTEM TUMOR; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

CATHEPSIN B; CENTRAL NERVOUS SYSTEM NEOPLASMS; ENDOPEPTIDASES; GLIOMA; HUMANS; MATRIX METALLOPROTEINASES; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PLASMINOGEN ACTIVATORS; RECEPTORS, CELL SURFACE; URINARY PLASMINOGEN ACTIVATOR;

EID: 0041737535     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1121     Document Type: Review

References (146)

1. Avgeropoulos, N. G., Batchelor, T. T. New treatment strategies for malignant gliomas. Oncologist 4, 209-224 (1999).
2. Sheline, G. E. Tumors of the Brain (ed. Blehen, N. M.) 83-99 (Springer-Verlag, Berlin, 1986).
3. Barker, F. G. et al. Age and radiation response in glioblastoma multiforme. Neourosurgery 49, 1288-1298 (2001).
4. Bignami, A. & Asher, R. Some observations on the localization of hyaluronic acid in adult, newborn and embryonal rat brain. Int. J. Dev. Neurosci. 10, 45-57 (1992).
5. Dano, K. et al. Plasminogen activators, tissue degradation and cancer. Adv. Cancer Res. 44, 139-266 (1985).
6. Naldini, L. et al. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J. 11, 4825-4833 (1992).
7. Nielsen, L. S., Andreasen, P. A., Grondahl-Hansen, J., Skriver, L. & Dano, K. Plasminogen activators catalyse conversion of inhibitor from fibrosarcoma cells to an inactive form with a lower apparent molecular mass. FEBS Lett. 196, 269-273 (1985).
8. Vassalli, J. D., Baccino, D. & Belin, D. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J. Cell Biol. 100, 86-92 (1985).
9. Zhou, H. M., Nichols, A., Meda, P. & Vassalli, J. D. Urokinase-type plasminogen activator and its receptor synergize to promote pathogenic proteolysis. EMBO J. 19, 4817-4826 (2000).
10. Ossowski, L. & Aguirre-Ghiso, J. A. Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr. Opin. Cell Biol. 12, 613-620 (2000).
11. Sidenius, N., Andolfo, A., Fesce, R. & Blasi, F. Urokinase regulates vitronectin binding by controlling urokinase receptor oligomerization. J. Biol. Chem. 277, 27982-27990 (2002).
12. Blasi, F. & Carmeliet, P. uPAR: a versatile signalling orchestrator. Nature Rev. Mol. Cell Biol. 3, 932-943 (2002).
13. Resnati, M. et al. The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc. Natl Acad. Sci. USA 99, 1359-1364 (2002).
14. Yamamoto, M. et al. Expression and localization of urokinase-type plasminogen activator in human astrocytomas in vivo. Cancer Res. 54, 3656-3661 (1994).
15. Gladson, C. L., Pijuan-Thompson, V., Olman, M. A., Gillespie, G. Y. & Yacoub, I. Z. Up-regulation of urokinase and urokinase receptor genes in malignant astrocytoma. Am. J. Pathol. 146, 1150-1160 (1995).
16. Lakka, S. S., Bhattacharya, A., Mohanam, S., Boyd, D. & Rao, J. S. Regulation of the uPA gene in various grades of human glioma cells. Int. J. Oncol. 18, 71-79 (2001).
17. Arai, Y. et al. Production of urokinase-type plasminogen activator (u-PA) and plasminogen activator inhibitor-1 (PAI-1) in human brain tumours. Acta Neurochir. (Wien) 140, 377-385 (1998).
18. Zhang, X. et al. Expression and localisation of urokinase-type plasminogen activator gene in gliomas. J. Clin. Neurosci. 7, 116-119 (2000).
19. Mohanam, S. et al. Elevated levels of urokinase-type plasminogen activator and its receptor during tumor growth in vivo. Int. J. Oncol. 14, 169-174 (1999).
20. Mohanam, S. et al. Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody. Cancer Res. 53, 4143-4147 (1993).
21. Yamamoto, M. et al. Expression and localization of urokinase-type plasminogen activator receptor in human gliomas. Cancer Res. 54, 5016-5020 (1994). Showed that expression of urokinase-type plasminogen activator (uPA) was significantly higher in anaplastic astrocytomas and glioblastomas, and uPA receptor (uPAR) mRNA was localized in astrocytoma cells and endothelial cells in the tumour tissue, which indicates that the expression of uPAR by invading astrocytoma cells might be important for the invasive behaviour of glioblastomas.
22. Czekay, R. P. et al. Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity. Mol. Biol. Cell 12, 1467-1479 (2001).
23. Yamamoto, M. et al. Expression and cellular localization of low-density lipoprotein receptor-related protein/α2-macroglobulin receptor in human glioblastoma in vivo. Brain Tumor Pathol. 15, 23-30 (1998).
24. Mori, T. et al. Up-regulation of urokinase-type plasminogen activator and its receptor correlates with enhanced invasion activity of human glioma cells mediated by transforming growth factor-α or basic fibroblast growth factor. J. Neurooncol. 46, 115-123 (2000).
25. Bhattacharya, A., Lakka, S. S., Mohanam, S., Boyd, D. & Rao, J. S. Regulation of the urokinase-type plasminogen activator receptor gene in different grades of human glioma cell lines. Clin. Cancer Res. 7, 267-276 (2001).
26. Mohanam, S. et al. Increased invasion of neuroglioma cells transfected with urokinase plasminogen activator receptor cDNA. Int. J. Oncol. 13, 1285-1290 (1998).
27. Engelhard, H., Narang, C., Homer, R. & Duncan, H. Urokinase antisense oligodeoxynucleotides as a novel therapeutic agent for malignant glioma: in vitro and in vivo studies of uptake, effects and toxicity. Biochem. Biophys. Res. Commun. 227, 400-405 (1996).
28. Engelhard, H. H., Homer, R. J., Duncan, H. A. & Rozental, J. Inhibitory effects of phenylbutyrate on the proliferation, morphology, migration and invasiveness of malignant glioma cells. J. Neurooncol. 37, 97-108 (1998).
29. Mishima, K. et al. A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin. Proc. Natl Acad. Sci. USA 97, 8484-8489 (2000). Showed that a peptide derived from the connecting peptide region of uPA inhibits endothelial-cell migration in vitro and tumour angiogenesis in vivo and has potential for clinical use.
30. Mohanam, S. et al. Stable transfection of urokinase-type plasminogen activator antisense construct modulates invasion of human glioblastoma cells. Clin. Cancer Res. 7, 2519-2526 (2001).
31. Mohanam, S. et al. Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator. Oncogene 21, 7824-7830 (2002).
32. Mohanam, S. et al. In vitro inhibition of human glioblastoma cell line invasiveness by antisense uPA receptor. Oncogene 14, 1351-1359 (1997). Showed that uPAR expression was reduced in glioblastoma cell lines stably transfected with antisense-uPAR. These cells had a low level of invasion and migration compared with controls. However, there was no difference in uPA activity. Matrix metalloproteinase 2 (MMP2) activity was decreased in antisense-expressing clones compared with controls.
33. Go, Y. et al. Inhibition of in vivo tumorigenicity and invasiveness of a human glioblastoma cell line transfected with antisense uPAR vectors. Clin. Exp. Metastasis 15, 440-446 (1997).
34. Mohan, P. M. et al. Adenovirus-mediated delivery of antisense gene to urokinase-type plasminogen activator receptor suppresses glioma invasion and tumor growth. Cancer Res. 59, 3369-3373 (1999).
35. Chintala, S. K. et al. Altered in vitro spreading and cytoskeletal organization in human glioma cells by downregulation of urokinase receptor. Mol. Carcinog. 20, 355-365 (1997).
36. MacDonald, T. J., DeClerck, Y. A. & Laug, W. E. Urokinase induces receptor mediated brain tumor cell migration and invasion. J. Neurooncol. 40, 215-226 (1998).
37. Hedberg, K. K., Stauff, C., Hoyer-Hansen, G., Ronne, E. & Griffith, O. H. High-molecular-weight serum protein complexes differentially promote cell migration and the focal adhesion localization of the urokinase receptor in human glioma cells. Exp. Cell Res. 257, 67-81 (2000).
38. Kin, Y. et al. A novel role for the urokinase-type plasminogen activator receptor in apoptosis of malignant gliomas. Int. J. Oncol. 17, 61-65 (2000).
39. Yanamandra, N. et al. Downregulation of urokinase-type plasminogen activator receptor (uPAR) induces caspase-mediated cell death in human glioblastoma cells. Clin. Exp. Metastasis 18, 611-615 (2000).
40. Krishnamoorthy, B. et al. Glioma cells deficient in urokinase plaminogen activator receptor expression are susceptible to tumor necrosis factor-α-related apoptosis-inducing ligand-induced apoptosis. Clin. Cancer Res 7, 4195-4201 (2001).
41. Fahraeus, R. & Lane, D. P. The p16(INK4a) tumour suppressor protein inhibits αvβ3 integrin-mediated cell spreading on vitronectin by blocking PKC-dependent localization of αvβ3 to focal contacts. EMBO J. 18, 2106-2118 (1999).
42. Adachi, Y. et al. Down-regulation of integrin αvβ3 expression and integrin-mediated signaling in glioma cells by adenovirus-mediated transfer of antisense urokinase-type plasminogen activator receptor (uPAR) and sense p16 genes. J. Biol. Chem. 276, 47171-47177 (2001). The authors infected the malignant glioma cell line SNB19 with the adenovirus vectors Ad-uPAR, Ad-INK4A or Ad-uPAR-INK4A in the presence of vitronectin, and showed that this resulted in decreased expression of αvβ3 integrin and decreased integrin-mediated biological effects, including adhesion, migration, proliferation and survival.
43. Adachi, Y. et al. Suppression of glioma invasion and growth by adenovirus-mediated delivery of a bicistronic construct containing antisense uPAR and sense p16 gene sequences. Oncogene 21, 87-95 (2002).
44. Vallera, D. A., Li, C., Jin, N., Panoskaltsis-Mortari, A. & Hall, W. A. Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT. J. Natl. Cancer Inst. 94, 597-606 (2002). This paper showed that DTAT was highly potent and selective in killing uPAR-expressing glioblastoma cells and human umbilical-vein endothelial cells in vitro and caused a statistically significant regression of small U118MG tumours in all mice in vivo with no systemic effects.
45. Alonso, D. F., Tejera, A. M., Farias, E. F., Bal de Kier, J. E. & Gomez, D. E. Inhibition of mammary tumor cell adhesion, migration, and invasion by the selective synthetic urokinase inhibitor B428. Anticancer Res. 18, 4499-4504 (1998).
46. Sturzebecher, J. et al. 3-Amidinophenylalanine-based inhibitors of urokinase. Bioorg. Med. Chem. Lett. 9, 3147-3152 (1999).
47. Evans, D. M., Sloan-Stakleff, K., Arvan, M. & Guyton, D. P. Time and dose dependency of the suppression of pulmonary metastases of rat mammary cancer by amiloride. Clin. Exp. Metastasis 16, 353-357 (1998).
48. Behrendt, N., Ronne, E. & Dano, K. Binding of the urokinase-type plasminogen activator to its cell surface receptor is inhibited by low doses of suramin. J. Biol. Chem. 268, 5985-5989 (1993).
49. Sato, S. et al. High-affinity urokinase-derived cyclic peptides inhibiting urokinase/urokinase receptor-interaction: effects on tumor growth and spread. FEBS Lett. 528, 212-216 (2002).
50. Shingleton, W. D., Hodges, D. J., Brick, P. & Cawston, T. E. Collagenase: a key enzyme in collagen turnover. Biochem. Cell Biol. 74, 759-775 (1996).
51. Overall, C. M. Molecular determinants of metalloproteinase substrate specificity: matrix metalloproteinase substrate binding domains, modules, and exosites. Mol. Biotechnol. 22, 51-86 (2002).
52. Gomez, D. E., Alonso, D. F., Yoshiji, H. & Thorgeirsson, U. P. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur. J. Cell. Biol. 74, 111-122 (1997).
53. Westermarck, J. & Kahari, V.-M. Regulation of matrix metalloproteinase expression in tumour invasion. FASEB J. 13, 781-792 (1999).
54. Westermarck, J., Seth, A. & Kahari, V. M. Differential regulation of interstitial collagenase (MMP-1) gene expression by ETS transcription factors. Oncogene 14, 2651-2660 (1997).
55. Yabkowitz, R. et al. Inflammatory cytokines and vascular endothelial growth factor stimulate the release of soluble tie receptor from human endothelial cells via metalloprotease activation. Blood 93, 1969-1979 (1999).
56. Chintala, S. K. et al. Induction of matrix metalloproteinases-9 requires a polymerized actin cytoskeleton in human malignant glioma cells. J. Biol. Chem. 273, 13545-13551 (1998). This paper showed that cytochalasin-D treatment of SNB19 cells resulted in the loss of PMA-induced MMP9 expression and actin polymerization, resulting in cell rounding. MMP9 expression was also inhibited by calphostin-C, a protein-kinase inhibitor, which indicates the involvement of protein kinase C in MMP9 expression.
57. Wilson, C. L., Heppner, K. J., Labosky, P. A., Hogan, B. L & Matrisian, L. M. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc. Natl. Acad. Sci. USA 94, 1402-1407 (1997).
58. Masson, R. et al. In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy. J. Cell Biol. 140, 1535-1541 (1998).
59. Itoh, T. et al. Experimental metastasis is suppressed in MMP-g-deficient mice. Clin. Exp. Metastasis 17, 177-181 (1999).
60. Itoh, T. et al. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. 58, 1048-1051 (1998).
61. Sternlicht, M. D. & Werb, Z. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell. Dev. Biol. 17, 463-516 (2001).
62. Coussens, L. M., Tinkle, C. L., Hanahan, D. & Werb, Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103, 481-490 (2000). The authors showed that MMP9 expressed by inflammatory cells is functionally involved in the regulation of oncogene-induced keratinocyte hyperproliferation, progression to invasive cancer and end-stage malignant grade in K14-HPV16 transgenic mice.
63. Bergers, G. et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biol. 2, 737-744 (2000).
64. Chandrasekar, N. et al. Modulation of endothelial cell morphogenesis in vitro by MMP-9 during glial-endothelial cell interactions. Clin. Exp. Metastasis 18, 337-342 (2000).
65. Tanaka, K., Abe, M. & Sato, Y. Roles of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase in the signal transduction of basic fibroblast growth factor in endothelial cells during angiogenesis. Jpn J. Cancer Res. 90, 647-654 (1999).
66. McCawley, L. J. & Matrisian, L. M. Matrix metalloproteinases: they're not just for matrix anymore! Curr. Opin. Cell Biol. 13, 534-540 (2001).
67. Platten, M., Wick, W. & Weller, M. Malignant glioma biology: role for TGF-β in growth, motility, angiogenesis and immune escape. Microsc. Res. Tech. 52, 401-410 (2001).
68. Rao, J. S. et al. Elevated levels of M 92,000 type IV collagenase in human brain tumors. Cancer Res. 53, 2208-2211 (1993).
69. Forsyth, P. A. et al. Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br. J. Cancer 79, 1828-1835 (1999).
70. Rooprai, H. K. & McCormick, D. Proteases and their inhibitors in human brain tumours: a review. Anticancer Res. 17, 4151-4162 (1997).
71. Vos, C. M. et al. Matrix metalloprotease-9 release from monocytes increases as a function of differentiation: implications for neuroinflammation and neurodegeneration. J. Neuroimmunol. 109, 221-227 (2000).
72. Sawaya, R. E. et al. Expression and localization of 72 kDa type IV collagenase (MMP-2) in human malignant gliomas in vivo. Clin. Exp. Metastasis 14, 35-42 (1996).
73. Sawaya, R. et al. Elevated levels of Mr 92,000 type IV collagenase during tumor growth in vivo. Biochem. Biophys. Res. Commun. 251, 632-636 (1998).
74. Lakka, S. S. et al. Regulation of MMP-9 (type IV collagenase) production and invasiveness in gliomas by the extracellular signal-regulated kinase and jun amino-terminal kinase signaling cascades. Clin. Exp. Metastasis 18, 245-252 (2000).
75. Choe, G. et al. Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype. Clin. Cancer Res. 8, 2894-2901 (2002).
76. Ellerbrook, S. M. et al. Phosphatidyl inositol 3-kinase activity in epidermal growth factor stimulated matrix metallproteinases-9 production and cell surface association. Cancer Res. 61, 1855-1861 (2001).
77. Park, M. J. et al. PTEN suppresses hyaluronic acid-induced matrix metalloproteinase-9 expression in U87MG glioblastoma cells through focal adhesion kinase dephosphorylation. Cancer Res. 62, 6318-6322 (2002).
78. Chintala, S. K. et al. Altered actin cytoskeleton and inhibition of matrix metalloproteinase expression by vanadate and phenylarsine oxide, inhibitors of phosphotyrosine phosphatases: modulation of migration and invasion of human malignant glioma cells. Mol. Carcinog. 26, 274-285 (1999).
79. Kondraganti, S. et al. Selective suppression of matrix metalloproteinase-9 in human glioblastoma cells by antisense gene transfer impairs glioblastoma cell invasion. Cancer Res. 60, 6851-6855 (2000). Showed that SNB19 stable transfectants for antisense-MMP9 expressed decreased levels of MMP9 protein and mRNA. Invasion in vitro and intracranial tumour growth in vivo were also inhibited in these stable antisense-expressing cells, indicating the role of MMP9 in tumour growth and invasion.
80. Lakka, S. S. et al. Adenovirus-mediated expression of antisense MMP-9 in glioma cells inhibits tumor growth and invasion. Oncogene 21, 8011-8019 (2002).
81. Brand, K. et al. Treatment of colorectal liver metastases by adenoviral transfer of tissue inhibitor of metalloproteinases-2 into the liver tissue. Cancer Res. 60, 5723-5730 (2000).
82. Celiker, M. Y. et al. Inhibition of Wilms' tumor growth by intramuscular administration of tissue inhibitor of metalloproteinases-4 plasmid DNA. Oncogene 20, 4337-4343 (2001).
83. Rao, J. S. et al. Role of plasminogen activator and of 92-kDa type IV collagenase in glioblastoma invasion using an in vitro matrigel model. J. Neurooncol. 18, 129-138 (1994).
84. Matsuzawa, K., Fukuyama, K., Hubbard, S. L., Dirks, P. B. & Rutka, J. T. Transfection of an invasive human astrocytoma cell line with a TIMP-1 cDNA: modulation of astrocytoma invasive potential. J. Neuropathol. Exp. Neurol. 55, 88-96 (1996).
85. Valente, P. et al. TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int. J. Cancer 75, 246-253 (1998).
86. Wang, Z., Juttermann, R. & Soloway, P. D. TIMP-2 is required for efficient activation of proMMP-2 in vivo. J. Biol. Chem. 275, 26411-26415 (2000).
87. Yoshiji, H. et al. Vascular endothelial growth factor tightly regulates in vivo development of murine hepatocellular carcinoma cells. Hepatology 28, 1489-1496 (1998).
88. Price, A. et al. Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340. Clin. Cancer Res. 5, 845-854 (1999).
89. Tonn, J. C. et al. Effect of synthetic matrix-metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas in vitro. Int. J. Cancer 80, 764-772 (1999).
90. Coussens, L. M., Fingleton, B. & Matrisian, L. M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295, 2387-2392 (2002).
91. Johansson, N. et al. Expression of collagenase-3 (MMP-13) and collagenase-1 (MMP-1) by transformed keratinocytes is dependent on the activity of p38 mitogen-activated protein kinase. J. Cell Sci. 113, 227-235 (2000).
92. Shin, M., Yan, C. & Boyd, D. An inhibitor of c-jun aminoterminal kinase (SP600125) represses c-Jun activation, DNA-binding and PMA-inducible 92-kDa type IV collagenase expression. Biochim. Biophys. Acta 1589, 311-316 (2002).
93. Lakka, S. S. et al. Downregulation of MMP-9 in ERK-mutated stable transfectants inhibits glioma invasion in vitro. Oncogene 21, 5601-5608 (2002). Shows that the ERK-dependent signalling pathway seems to regulate MMP-9 mediated glioma invasion.
94. Sun, Y. et al. Wild-type and mutant p53 differentially regulate the gene expression of human collagenase-3 (hMMP-13). J. Biol. Chem. 275, 11327-11332 (2000).
95. Park, M. J. et al. PTEN suppresses hyaluronic acid-induced matrix metalloproteinase-9 expression in U87MG glioblastoma cells through focal adhesion kinase dephosphorylation. Cancer Res. 62, 6318-6322 (2002). Showed that hyaluronic acid induces the invasion of glioma cells by the induction of MMP9 through the FAK-ERK1/ERK2 signalling pathway. Introduction of a functional PTEN gene decreases these effects, and the protein-phosphatase activity of PTEN is crucial for these events.
96. Koul, D. et al. Suppression of matrix metalloproteinase-2 gene expression and invasion in human glioma cells by MMAC/PTEN. Oncogene 20, 6669-6678 (2001).
97. Lund, L. R. et al. Functional overlap between two classes of matrix-degrading proteases in wound healing. EMBO J. 18, 4645-4656 (1999). The authors show that both plasminogen deficiency and MMP inhibition are required for complete inhibition of the healing process. This indicates that there is a functional overlap between the two classes of matrix-degrading proteases. The strong similarities between the proteolytic mechanisms in wound healing and cancer invasion indicate that cancer therapy will require the use of inhibitors of both classes of protease.
98. Rooprai, H. K. et al. The role of integrin receptors in aspects of glioma invasion in vitro. Int. J. Dev. Neurosci. 17, 613-623 (1999).
99. Chintala, S. K., Sawaya, R., Gokaslan, Z. L. & Rao, J. S. Modulation of matrix metalloprotease-2 and invasion in human glioma cells by α3β1 integrin. Cancer Lett. 103, 201-208 (1996).
100. Silletti, S., Kessler, T., Goldberg, J., Boger, D. L. & Cheresh, D. A. Disruption of matrix metalloproteinase 2 binding to integrin αvβ3 by an organic molecule inhibits angiogenesis and tumor growth in vivo. Proc. Natl Acad. Sci. USA 98, 119-124 (2001).
101. Rooprai, H. K. et al. Evaluation of the effects of swainsonine, captopril, tangeretin and nobiletin on the biological behaviour of brain tumour cells in vitro. Neuropathol. Appl. Neurobiol. 27, 29-39 (2001).
102. Kirschke, H., Barrett, A. J. & Rawlings, N. D. Proteinases 1: lysosomal cysteine proteinases. Protein Profile 2, 1581-1643 (1995).
103. Sloane, B. F. et al, in Biological Functions of Proteases and Inhibitors (eds Katunama, N., Suzuki, J., Travis, J. & Fritz, H.) 131-147 (Scientific Societies Press, Tokyo, Japan, 1994).
104. Qian, F., Frankfater, A., Chan, S. J. & Steiner, D. F. The structure of the mouse cathepsin B gene and its putative promoter. DNA Cell Biol. 10, 159-168 (1991).
105. Yan, S., Berquin, I. M., Troen, B. R. & Sloane, B. F. Transcription of human cathepsin B is mediated by Sp1 and Ets family factors in glioma. DNA Cell Biol. 19, 79-91 (2000).
106. Konduri, S. et al. Elevated levels of cathepsin B in human glioblastoma cell lines. Int. J. Oncol. 19, 519-524 (2001).
107. Spless, E. et al. Cathepsin B activity in human lung tumor cell lines: ultrastructural localization, pH sensitivity and inhibitor status at the cellular level. J. Histochem. Cytochem. 42, 917-929 (1994).
108. Kobayashi, H. et al. Inhibition of in vitro ovarian cancer cell invasion by modulation of urokinase-type plasminogen activator and cathepsin B. Cancer Res. 52, 3610-3614 (1992).
109. Koblinski, J. E. et al. Interaction of human breast fibroblasts with collagen I increases secretion of procathepsin B. J. Biol. Chem. 277, 32220-32227 (2002).
110. Somanna, A., Mundodi, V. & Gedamu, L. Functional analysis of cathepsin B-like cysteine proteases from Leishmania donovani complex. Evidence for the activation of latent transforming growth factor-β. J. Biol. Chem. 277, 25305-25312 (2002). The authors used the cathepsin-B-specific inhibitor CA074 and antisense mRNA to show that Leishmania cathepsin B has a role in survival and pathogenesis by activating latent TGF-β, thereby allowing the parasite to replicate in macrophages.
111. Eeckhout, Y. & Vaes, G. Further studies on the activation of procollagenase, the latent precursor of bone collagenase. Effects of lysosomal cathepsin B, plasmin and kallikrein, and spontaneous activation. Biochem. J. 166, 21-31 (1977).
112. Emmert-Buck, M. R. et al. Increased gelatinase A (MMP-2) and cathepsin B activity in invasive tumor regions of human colon cancer samples. Am. J. Pathol. 145, 1285-1290 (1994).
113. Kostoulas, G., Lang, A., Nagase, H. & Baici, A. Stimulation of angiogenesis through cathepsin B inactivation of the tissue inhibitors of matrix metalloproteinases. FEBS Lett. 455, 286-290 (1999).
114. Kostoulas, G., Lang, A., Nagase, H. & Baici, A. Stimulation of angiogenesis through cathepsin B inactivation of the tissue inhibitors of matrix metalloproteinases. FEBS Lett. 455, 286-290 (1999).
115. McCormick, D. Secretion of cathepsin B by human gliomas in vitro. Neuropathol. Appl. Neurobiol. 19, 146-151 (1993).
116. Rempel, S. A. et al. Cathepsin B expression and localization in glioma progression and invasion. Cancer Res. 54, 6027-6031 (1994).
117. Sivaparvathi, M. et al. Overexpression and localization of cathepsin B during the progression of human gliomas. Clin. Exp. Metastasis 13, 49-56 (1995).
118. Mikkelsen, T. et al. Immunolocalization of cathepsin B in human glioma: implications for tumor invasion and angiogenesis. J. Neurosurg. 83, 285-290 (1995).
119. Strojnik, T., Kos, J., Zidanik, B., Golouh, R. & Lah, T. Cathepsin B immunohistochemical staining in tumor and endothelial cells is a new prognostic factor for survival in patients with brain tumors. Clin. Cancer Res 5, 559-567 (1999). The authors showed that high expression levels of cathepsin B correlate with poor clinical outcome. The expression of cathepsin B by endothelial cells might be used to predict the survival of glioblastoma patients and, in addition, it indicates the involvement of cathepsin B in tumour-associated angiogenesis.
120. Demchik, L. L., Sameni, M., Nelson, K., Mikkelsen, T. & Sloane, B. F. Cathepsin B and glioma invasion. Int. J. Dev. Neurosci. 17, 483-494 (1999).
121. Mohanam, S. et al. Down-regulation of cathepsin B expression impairs the invasive and tumorigenic potential of human glioblastoma cells. Oncogene 20, 3665-3673 (2001). The authors showed that SNB19-stable clones expressing antisense cathepsin B cDNA had significant reductions in the levels of cathepsin B mRNA, enzyme activity and protein compared with controls. These cells had reduced invasiveness in vitro, and intracerebral injection of these antisense clones resulted in reduced tumour formation in nude mice.
122. Turk, B., Turk, V. & Turk, D. Structural and functional aspects of papain-like cysteine proteinases and their protein inhibitors. Biol. Chem. 378, 141-150 (1997).
123. Sivaparvathi, M., McCutcheon, I., Sawaya, R., Nicolson, G. L. & Rao, J. S. Expression of cysteine protease inhibitors in human gliomas and meningiomas. Clin. Exp. Metastasis 14, 344-350 (1996).
124. Strojnik, T. et al. Cathepsin B and its inhibitor stefin A in brain tumors. Pflugers Arch. 439, R122-R123 (2000).
125. Konduri, S. D. et al. Modulation of cystatin C expression impairs the invasive and tumorigenic potential of human glioblastoma cells. Oncogene 21, 8705-8712 (2002).
126. Tysnes, B. B. & Mahesparan, R. Biological mechanisms of glioma invasion and potential therapeutic targets. J. Neurooncol. 53, 129-147 (2001).
127. Ossowski, L. & Aguirre-Ghiso, J. A. Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr. Opin. Cell Biol. 12, 613-620 (2000).
128. Goldbrunner, R. H., Bernstein, J. J. & Tonn, J. C. ECM-mediated glioma cell invasion. Microsc. Res. Tech. 43, 250-257 (1998).
129. Rutka, J. T., Apodaca, G., Stern, R. & Rosenblum, M. The extracellular matrix of the central and peripheral nervous systems: structure and function. J. Neurosurg. 69, 155-170 (1988).
130. Fryer, H. J., Kelly, G. M., Molinaro, L. & Hockfield, S. The high molecular weight Cat-301 chondroitin sulfate proteoglycan from brain is related to the large aggregating proteoglycan from cartilage, aggrecan. J. Biol. Chem. 267, 9874-9883 (1992).
131. Aquino, D. A., Margolis, R. U. & Jargolis, R. K. Immunocytochemical localization of a chondroitin sulfate proteoglycan in nervous tissue. II. Studies in developing brain. J. Cell Biol. 99, 1130-1139 (1984).
132. Margolis, R. K. & Margolis, R. U. in Complex Carbohydrates of Nervous Tissue (eds Margolis, R. K. & Margolis, R. U.) 45-73 (Plenum Press, New York, 1979).
133. Buckley, K. M. et al. A synaptic vesicle antigen is restricted to the junctional region of the presynaptic plasma membrane. Proc. Natl Acad. Sci. USA 80, 7342-7346 (1983).
134. Bunge, R. P. & Bunge, M. B. Interrelationship between Schwann cell function and extracellular matrix production. Trends Neurosci. 6, 499-505 (1983).
135. Rollins, B. J., Cathcart, M. K. & Culp, L. A. in The Glycoconjugate (ed. Harowitz, M. I.) 289-329 (Academic Press, New York, 1982).
136. Iozzo, B. P. Proteoglycans and neoplastic-mesenchymal cell interactions. Hum. Pathol. 15, 2-10 (1984).
137. Toole, B. P., Goldberg, R. L., Chi-Rosso, G., Underhill, C. B. & Orkin, R. W. in The Role of Extracellular Matrix in Development (ed. Trelstad, R. L.) 43-66 (Liss, New York, 1984).
138. Burger, P. C., Heinz, E. R., Shibata, T. & Kleihues, P. Topographic anatomy and CT correlations in the untreated glioblastoma multiforme. J. Neurosurg. 68, 698-704 (1988).
139. Chintala, S. K., Sawaya, R., Gokaslan, Z. L., Fuller, G. & Rao, J. S. Immmunohistochemical localization of extracellular matrix proteins in human glioma, both in vivo and in vitro. Cancer Lett. 101, 107-114 (1996).
140. Ruosssslahti, E. & Pierschbacher, M. D. New perspectives in cell adhesion: RGD and integrins. Science 238, 491-497 (1987).
141. Gladson, C. L. & Cheresh, D. A. Glioblastoma expression of vitronectin and the αvβ3 integrin. Adhesion mechanism for transformed glial cells. J. Clin. Invest. 88, 1924-1932 (1991).
142. Berens, M. E., Rief, M. D., Loo, M. A. & Giese, A. The role of extracellular matrix in human astrocytoma migration and proliferation studies in a microliter scale assay. Clin. Exp. Metastasis 12, 405-415 (1994).
143. Tucker, R. P. The in situ localization of tenascin splice variants and thrombospondin 2 mRNA in the avian embryo. Development 117, 347-358 (1993).
144. Wehrle-Haller, B., Koch, M., Baumgartner, S., Spring, J. & Chiquet, M. Nerve-dependent and -indepdent tenascin expression in the developing chick limb bud. Development 112, 627-637 (1991).
145. Prieto, A. L., Edelman, G. M. & Crossin, K. L. Multiple integrins mediate cell attachment to cytotactin/tenascin. Proc. Natl Acad. Sci. USA 90, 10154-10158 (1993). Shows that the third fibronectin type III repeat, which contains the RGD tripeptide, supports cell attachment and migration of gliomas, and interaction with many integrins mediates the binding of different cell types to chicken cytotactin. The use of RGD-containing peptides and well-characterized antibodies specific for integrins indicates that cell attachment to the third fibronectin type III repeat is mediated by at least two integrin receptors of the αv subtype.
146. Yurchenco, P. D. & Schittny, J. C. Molecular architecture of basement membranes. FASEB J. 4, 1577-1590 (1990).